Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis

INTRODUCTION: Psoriatic arthritis (PsA) affects around 150 000 people in the UK of whom around 50% require treatment with biologics. The most used biologics for PsA target tumour necrosis factor (TNF) or interleukin-17A (IL-17A). About 50% of patients respond to each, but it is not currently possibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooms, Alexander, Al-Mossawi, Hussein, Bennett, Louise, Bogale, Mimi, Bowness, Paul, Francis, Anne, Goodyear, Carl, Kirkham, Bruce W, Lalnunhlimi, Sylvine, McInnes, Iain B, Richards, Duncan, Siebert, Stefan, Taams, Leonie S, Tulunay Virlan, Aysin, Yager, Nicole, Coates, Laura C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546161/
https://www.ncbi.nlm.nih.gov/pubmed/37770264
http://dx.doi.org/10.1136/bmjopen-2023-078539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546161/
https://www.ncbi.nlm.nih.gov/pubmed/37770264
http://dx.doi.org/10.1136/bmjopen-2023-078539

Ejemplares similares